BloodJClub
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.
Blood · · Journal Article · Open access
Gil, Sargas + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
High NPM1 variant allele frequency (VAF) above 31.44% predicts better survival in NPM1-mutated AML patients.
- Why it matters: Current risk stratification for NPM1-mutated AML does not fully account for heterogeneity in outcomes, highlighting the need for more precise prognostic markers.
- What they did: The study analyzed 688 patients, integrating VAF, mutation order, and clonal architecture using PyClone and ClonEvol, to identify prognostic significance of quantitative clonal features.
- The result: NPM1low status was associated with worse overall and relapse-free survival, while specific mutation burdens and clonal structures, including intraclonal colocalization patterns, further refined outcome predictions.
The findingWhy it mattersWhat they didThe result
- Open access